Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - NO.
Peripheral Vasculitis, Intermediate Uveitis and Interferon Use in Multiple Sclerosis.
Sparing of tissue by using micro-slit-beam radiation therapy reduces neurotoxicity compared with broad-beam radiation therapy.
Age-Related Uptake of Heavy Metals in Human Spinal Interneurons.
Enterococcus faecium strain L-3 and glatiramer acetate ameliorate experimental allergic encephalomyelitis in rats by affecting different populations of immune cells.
Utilization of PET imaging in differential diagnostics between a tumefactive multiple sclerosis lesion and low-grade glioma.
The role of autophagy in the pathogenesis of systemic lupus erythematosus.
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.
Mapping face encoding using functional MRI in multiple sclerosis across disease phenotypes.
N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
Health Utilities for Multiple Sclerosis.
Peptidyl Arginine Deiminases and Neurodegenerative Diseases.
Neuroprotective effects of various doses of topiramate against methylphenidate induced oxidative stress and inflammation in rat isolated hippocampus.
SOX10 Regulates an Alternative Promoter at the Charcot-Marie-Tooth Disease Locus MTMR2.
Demyelinizing Neurological Disease after Treatment with Tumor Necrosis Factor-α Antagonists.
Role of tolvaptan in the management of hyponatremia in patients with lung and other cancers: current data and future perspectives.
Sensory information treatment during disturbed standing posture in chronic acquired demyelinating polyneuropathies (CADP).
Poster 347 Physical Therapy Utilization in the Management of Multiple Sclerosis in the United States.
Prothrombin and factor X are elevated in multiple sclerosis patients.
Patient fibroblasts-derived induced neurons demonstrate autonomous neuronal defects in adult-onset Krabbe disease.
Zika virus infection and Guillain-Barré syndrome: a review focused on clinical and electrophysiological subtypes.
Taste dysfunction in multiple sclerosis.
US health insurance is an obstacle to disease-modifying treatments in MS.
Aquaporin-4 IgG autoimmune syndrome and immunoreactivity associated with thyroid cancer.
[Evaluation of repetitive transcranial magnetic stimulation effectiveness in treatment of psychiatric and neurologic diseases].
Pages
« first
‹ previous
…
795
796
797
798
799
800
801
802
803
…
next ›
last »